Advertisement


Taofeek Kunle Owonikoko, MD, PhD, on Small Cell Lung Cancer: Tremelimumab and Durvalumab With or Without Radiation

2019 ASCO Annual Meeting

Advertisement

Taofeek Kunle Owonikoko, MD, PhD, of Emory University, discusses the findings of his phase II study, which assessed the efficacy of combined immune checkpoint inhibitors with or without radiation in relapsed small cell lung cancer (Abstract 8515).



Related Videos

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, discusses study findings on the second-line use of lurbinectedin in patients with both resistant and sensitive small cell lung cancer (Abstract 8506).

Pancreatic Cancer

Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy

Alok A. Khorana, MD, of the Cleveland Clinic, and Hedy L. Kindler, MD, of The University of Chicago, discuss phase III findings on olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with metastatic pancreatic cancer and a germline BRCA mutation (Abstract LBA4).

Prostate Cancer

Ian D. Davis, MBBS, PhD, and Christopher Sweeney, MBBS, on Prostate Cancer: ENZAMET Trial on Enzalutamide for Metastatic Hormone-Sensitive Disease

Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss phase III findings from their international trial on adding enzalutamide as a new treatment option with testosterone suppression for metastatic hormone-sensitive prostate cancer (Abstract LBA2).

Prostate Cancer

Michael J. Morris, MD, on Metastatic Prostate Cancer: Adding Abiraterone Acetate to Enzalutamide

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses the phase III findings from the Alliance A031201 trial, which showed that adding abiraterone acetate to enzalutamide did not improve survival in men with metastatic castration-resistant prostate cancer (Abstract 5008).

Lymphoma
Immunotherapy

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings of the Smart Start study on the chemotherapy-free combination of rituximab, lenalidomide, and ibrutinib in newly diagnosed diffuse large B-cell lymphoma (Abstract 7508).

Advertisement

Advertisement




Advertisement